Michael Hudecek, MD: Engineering of chimeric antigen receptor(CAR)-modified T cells for immunotherapy of hematologic and solid tumors: Emerging opportunities and challenges
Thursday, 26th of February 2015, 10:00, Vienna Competence Center, Lazarettgasse 19, Vienna IX, seminar room, 1st floor
COLLOQUIUM IN PATHOPHYSIOLOGY, INFECTIOLOGY AND IMMUNOLOGY
Michael Hudecek studied medicine at Leipzig University where he focused his doctoral thesis work under the supervision of Dietger Niederwieser on the role of the minor histocompatibility antigen HA1 in graft versus leukemia reaction. For his postdoctoral studies he joined the lab of Stanley Riddell at the Fred Hutchinson Cancer Research Center in Seattle, USA, where he engineered tumor-reactive Chimeric Antigen Receptor (CAR) T cells for adoptive immunotherapy. He returned in 2012 to Germany as a resident physician to start his own lab at the Julius Maximilians University Medical School in Würzburg. Dr. Hudecek’s research interest encompass (1) the identification of tumor-associated antigens, (2) the engineering of tumor-specific CAR T cells and (3) adoptive immunotherapy with the use of CAR-T cells, tumor-specific T cells and antibodies."
Host: Ass.-Prof. Dr. Johannes Huppa
back to: CePII